i suspect he and friend tim sykes are front running stocks with their posts - ie pump and dump, or dis and cover. their recommendations seem to have shelf life of a day.
they have no choice as most of eggs are in p3. possibly a subgroup shows statistical improvement? but odds are against overall group. its literally like a lottery ticket - odds are against you but payoff can be huge.
comments welcome. doing dd
he is now shorting and has it as a sell. i suspect the only person making $ based on his recommendations is him as he goes for quick trades
"I will not receive cash (salary) compensation from my CEO role at $KBIO - I encourage other biotechnology companies to adopt this policy." MS tweet Nov 20
not so. look at pg 33 of proxy. do not double count middleton and sanderling shares. you get about 5.6M shares owned by insiders and 5% tutes, resulting in about 27% of outstanding shares. add in the smaller tutes are you are in the 30's%. change happens when you least expect it. STXS strong.
When it was $84 it had huge upside potential, perhaps to $1000 or more if drugs are successful. What drove it from $100 to current price are the toxic warrants. They basically increased shares by a factor of 10 from about 60 M to almost 700 M (or from 0.6 M to 7 M post split). Drop in share price merely resulted in todays market cap being similar to what it was in early part of year.
Most shares are not owned by funds, leaving room for activist or buyout at low price. While I agree that investment community exposure is terrible, unlike new company, STXS is now viewed as "show me" company. It needs to show much more rapid sales growth to attract investors - be they from tutes or from private small cap investors - some of whom have the means to take major stakess
A year ago (pre split) 60 M shares at $1 pps (or 0.6 M at $100 pps post split)
Today 7 M shares at $11.
Dilution/warrant brought it down in price. Why would it move up?
agree that he should not be both ceo and hedge fund manager. some of them are upset but have high tolerance for pain/mills sales is THE issue. if sales were growing much faster, company would be profitable and PPS would be much higher. Focus on sales starting with establishing much higher goals and replacing sales head with star performer. STXS Strong.
i can't see acension engaging in stxs stock manipulation - below its radar (ascension manages $29 B) and below its ethics (ascension is faith based/catholic organization). the only thing preventing broader ownership is mediocre sales growth. they should reorganize sales starting at the top. there are top performers who should be promoted and dead wood that should be replaced.
What proof do you have that SRS works for hedge fund and that he is short? From his posts, he is bullish on STXS and bearish on MIlls. The market seems to agree with him. If Duggan or Shkreli were Chairman and CEO, the share price would be north of $10 imo.
Activist investor example: KBIO. Activist investor bought up stock, became CEO and Chairman, replaced BoD. He immediately aligned shareholder interests with his interests. Stock went from 60 cents to about $2 when he first disclosed interest and to $18 when he became majority shareholder and CEO and replaced BoD.
There are too many JS's running small caps - drawing high salaries with no vested interest. As a result of the latter they have no remorse about bleeding investors. Shkreli has a lot of skin in game which immediately aligns his interests with investor interests
the tweet says 10-12 cases (12 packs) not one. there are 1800 target stores in US (not sure how many supply product) more of a lost opportunity than a disaster. maybe they sell $250k worth of product when demand is $ millions. the key will be how quickly they respond.